Comparison

Maleimide-PEG8-Val-Ala-PAB-SNS032 European Partner

Item no. HY-161780
Manufacturer MedChem Express
Amount 1 ea
Category
Type Amino Acid Derivates
Specific against other
Citations [1]Cheung A, et al., Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. Clin Cancer Res. 2024 May 21.
Smiles O=C(C=CC1=O)N1CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@@H](C(C)C)C(N[C@@H](C)C(NC2=CC=C(COC(N3CCC(C(NC4=NC=C(SCC5=NC=C(C(C)(C)C)O5)S4)=O)CC3)=O)C=C2)=O)=O)=O)=O
Shipping Condition Room temperature
Available
Manufacturer - Type
ADC Related
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Category
Reference compound / Active compounds
Manufacturer - Targets
CDK; Drug-Linker Conjugates for ADC
Shipping Temperature
Room temperature
Molecular Weight
1274.50
Product Description
Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules[1].
Manufacturer - Research Area
Cancer
Manufacturer - Pathway
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Clinical information
No Development Reported
UNSPSC Code
12352203

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 ea
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close